Quick Answer
China SXT Pharmaceuticals, Inc. reported Gross Profit of $367.4 thousand for fiscal year 2025.
China SXT Pharmaceuticals, Inc. Gross Profit — Annual History
| Fiscal Year | Gross Profit | YoY Change |
|---|---|---|
| 2025 | $367.4K | -33.7% |
| 2024 | $554.0K | +30.0% |
| 2023 | $426.3K | -65.9% |
| 2022 | $1.25M | -55.9% |
| 2021 | $2.84M | +5.0% |
| 2020 | $2.70M | -41.4% |
| 2019 | $4.61M | +35.6% |
| 2018 | $3.40M | +47.1% |
| 2017 | $2.31M | — |
- China SXT Pharmaceuticals, Inc. showed a decrease of -33.7% in Gross Profit compared to the prior fiscal year.
- Over the 2017–2025 period, China SXT Pharmaceuticals, Inc.’s gross profit has declined by 84.1% (from $2.31 million to $367.4 thousand).
- The most recent figure is from China SXT Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 20-F), filed with the SEC on July 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: